University of Colorado develops nonhormonal therapy for menopause-related vaginal tissue damage

Researchers at the University of Colorado Anschutz have announced the development of a promising non‑hormonal therapy for women suffering from Genitourinary Syndrome of Menopause (GSM). GSM, a chronic condition that arises from the decline in estrogen levels during menopause, affects the vulva, vagina, and urinary tract. The syndrome commonly manifests as vaginal dryness, painful intercourse, and recurrent vaginal and urinary tract infections, leading to significant discomfort and reduced quality of life for many women.

The new treatment, still in the early stages of clinical evaluation, offers an alternative to hormone‑based options by targeting the underlying tissue changes without systemic estrogen exposure. Early laboratory studies have shown that the therapy can improve mucosal hydration and restore normal vaginal flora, potentially reducing the frequency of infections and alleviating pain. The research team plans to initiate larger clinical trials to assess efficacy, safety, and long‑term outcomes in a diverse population of postmenopausal women.

If subsequent trials confirm the preliminary findings, the therapy could broaden the range of effective interventions for GSM, providing a safer choice for women who cannot or prefer not to use hormonal treatments. The University of Colorado Anschutz team will continue to refine the formulation and pursue regulatory approval, aiming to make a non‑hormonal option widely available to those affected by this common menopausal condition.